PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Rhea-AI Summary

PolyPid (Nasdaq: PYPD) will report its first quarter 2024 financial results and operational highlights on May 8, 2024. The company aims to improve surgical outcomes and will host a conference call and webcast to discuss the results and business operations.

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, May 8, 2024
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BI6c0218de1fe64ed5b4d221783eb70bba
Webcast:	https://edge.media-server.com/mmc/p/34fyspqn

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

FAQ

When will PolyPid report its first quarter 2024 financial results?

PolyPid will report its first quarter 2024 financial results on May 8, 2024.

What is the ticker symbol for PolyPid?

The ticker symbol for PolyPid is PYPD.

How can I listen to the conference call and webcast?

You can listen to the conference call and webcast on Wednesday, May 8, 2024, at 8:30 AM Eastern Time. Register in advance for the call or listen via the webcast.

What is the focus of PolyPid as a company?

PolyPid is a late-stage biopharma company aiming to improve surgical outcomes.

Where is PolyPid headquartered?

PolyPid is headquartered in Petach Tikva, Israel.